SMAIO SA (ALSMA.PA) Fundamental Analysis & Valuation

EPA:ALSMA • FR0014005I80

Current stock price

7.8 EUR
+0.46 (+6.27%)
Last:

This ALSMA.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALSMA.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALSMA has reported negative net income.
  • In the past year ALSMA has reported a negative cash flow from operations.
  • In the past 5 years ALSMA reported 4 times negative net income.
  • In multiple years ALSMA reported negative operating cash flow during the last 5 years.
ALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • ALSMA has a worse Return On Assets (-13.39%) than 73.02% of its industry peers.
  • ALSMA has a worse Return On Equity (-25.00%) than 68.25% of its industry peers.
Industry RankSector Rank
ROA -13.39%
ROE -25%
ROIC N/A
ROA(3y)0.22%
ROA(5y)-14.26%
ROE(3y)-3.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSMA.PA Yearly ROA, ROE, ROICALSMA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • With an excellent Gross Margin value of 83.83%, ALSMA belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
  • ALSMA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ALSMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.54%
GM growth 5Y-12.33%
ALSMA.PA Yearly Profit, Operating, Gross MarginsALSMA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ALSMA.PA Health Analysis

2.1 Basic Checks

  • ALSMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALSMA has about the same amout of shares outstanding than it did 1 year ago.
  • ALSMA has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ALSMA has been reduced compared to a year ago.
ALSMA.PA Yearly Shares OutstandingALSMA.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
ALSMA.PA Yearly Total Debt VS Total AssetsALSMA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • ALSMA has an Altman-Z score of 4.60. This indicates that ALSMA is financially healthy and has little risk of bankruptcy at the moment.
  • ALSMA's Altman-Z score of 4.60 is fine compared to the rest of the industry. ALSMA outperforms 77.78% of its industry peers.
  • A Debt/Equity ratio of 0.33 indicates that ALSMA is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.33, ALSMA is in line with its industry, outperforming 55.56% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z 4.6
ROIC/WACCN/A
WACC7.83%
ALSMA.PA Yearly LT Debt VS Equity VS FCFALSMA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • ALSMA has a Current Ratio of 2.90. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.90, ALSMA is in the better half of the industry, outperforming 79.37% of the companies in the same industry.
  • ALSMA has a Quick Ratio of 2.50. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ALSMA (2.50) is better than 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.5
ALSMA.PA Yearly Current Assets VS Current LiabilitesALSMA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ALSMA.PA Growth Analysis

3.1 Past

  • ALSMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.05%, which is quite impressive.
  • ALSMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 130.31%.
  • Measured over the past years, ALSMA shows a very strong growth in Revenue. The Revenue has been growing by 69.73% on average per year.
EPS 1Y (TTM)36.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
Revenue 1Y (TTM)130.31%
Revenue growth 3Y37.17%
Revenue growth 5Y69.73%
Sales Q2Q%126.03%

3.2 Future

  • ALSMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.73% yearly.
  • Based on estimates for the next years, ALSMA will show a very strong growth in Revenue. The Revenue will grow by 36.55% on average per year.
EPS Next Y35%
EPS Next 2Y45.77%
EPS Next 3Y38.6%
EPS Next 5Y43.74%
Revenue Next Year67.27%
Revenue Next 2Y51.06%
Revenue Next 3Y45.24%
Revenue Next 5Y36.55%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALSMA.PA Yearly Revenue VS EstimatesALSMA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
ALSMA.PA Yearly EPS VS EstimatesALSMA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2 0.4 -0.4 0.6 0.8

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALSMA.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALSMA. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 151.46 indicates a quite expensive valuation of ALSMA.
  • 73.02% of the companies in the same industry are cheaper than ALSMA, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.51, ALSMA is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 151.46
ALSMA.PA Price Earnings VS Forward Price EarningsALSMA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSMA.PA Per share dataALSMA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • ALSMA's earnings are expected to grow with 38.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.77%
EPS Next 3Y38.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALSMA.PA Dividend Analysis

5.1 Amount

  • ALSMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALSMA.PA Fundamentals: All Metrics, Ratios and Statistics

SMAIO SA

EPA:ALSMA (4/17/2026, 7:00:00 PM)

7.8

+0.46 (+6.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners59.89%
Ins Owner ChangeN/A
Market Cap48.05M
Revenue(TTM)8.28M
Net Income(TTM)-1.85M
Analysts86
Price Target8.52 (9.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.76%
PT rev (3m)3.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-26.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 151.46
P/S 5.8
P/FCF N/A
P/OCF N/A
P/B 6.49
P/tB 9.46
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)0.05
Fwd EY0.66%
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.34
BVpS1.2
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -13.39%
ROE -25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.83%
FCFM N/A
ROA(3y)0.22%
ROA(5y)-14.26%
ROE(3y)-3.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.54%
GM growth 5Y-12.33%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 149.37%
Cap/Sales 22.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.9
Quick Ratio 2.5
Altman-Z 4.6
F-Score5
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)98.78%
Cap/Depr(5y)137.67%
Cap/Sales(3y)30.2%
Cap/Sales(5y)56.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
EPS Next Y35%
EPS Next 2Y45.77%
EPS Next 3Y38.6%
EPS Next 5Y43.74%
Revenue 1Y (TTM)130.31%
Revenue growth 3Y37.17%
Revenue growth 5Y69.73%
Sales Q2Q%126.03%
Revenue Next Year67.27%
Revenue Next 2Y51.06%
Revenue Next 3Y45.24%
Revenue Next 5Y36.55%
EBIT growth 1Y34.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78%
EBIT Next 3Y46.44%
EBIT Next 5Y44.66%
FCF growth 1Y-114.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-872.79%
OCF growth 3YN/A
OCF growth 5YN/A

SMAIO SA / ALSMA.PA Fundamental Analysis FAQ

What is the fundamental rating for ALSMA stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALSMA.PA.


Can you provide the valuation status for SMAIO SA?

ChartMill assigns a valuation rating of 1 / 10 to SMAIO SA (ALSMA.PA). This can be considered as Overvalued.


How profitable is SMAIO SA (ALSMA.PA) stock?

SMAIO SA (ALSMA.PA) has a profitability rating of 1 / 10.